Optimization of treatment outcome and exploration of new indication in anti-vascular endothelial growth factor therapy_Chinese Journal of Ocular Fundus Diseases

Authors：

 XuXun

Department of Ophthalmology, The First People's Hospital Affiliated to Shanghai JiaoTong University, Shanghai 200080, China;

Corresponding author：

XuXun, Email: xuxun@163.com

Keywords：

Angiogenesis inhibitors/therapeutic use; Antibodies; monoclonal/therapeutic use; Choroidal neovascularization/drug therapy; Retinal neovascularization/drug therapy

DOI：

10.3760/cma.j.issn.1005-1015.2015.01.002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Since anti-vascular endothelial growth factor (VEGF) therapy has recently become the first-line treatment of wet age related macular degeneration in China, as well as retinopathy of prematurity, neovascular glaucoma and macular edema secondary to diabetic retinopathy or retinal vein occlusion in other countries. It is worth thinking about that how to perform anti-VEGF treatment properly to benefit more patients. We reviewed the fields of clinical researches to explore the best role of anti-VEGF treatment in prevention and treatment of retinal disease in future.

Citation： XuXun. Optimization of treatment outcome and exploration of new indication in anti-vascular endothelial growth factor therapy. Chinese Journal of Ocular Fundus Diseases, 2015, 31(1): 3-5. doi: 10.3760/cma.j.issn.1005-1015.2015.01.002 Copy

1.	Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration[J]. Retina, 2006, 26(8):859-870.
2.	Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration:a report by the American Academy Of Ophthalmology[J]. Ophthalmology, 2008, 115(10):1837-1846.
3.	Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration:two-year results of the ANCHOR study[J]. Ophthalmology, 2009, 116(1):57-65.
4.	Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration:PIER study year 1[J]. Am J Ophthalmol, 2008, 145(2):239-248.
5.	Campochiaro PA, Hafiz G, Channa R, et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions:two-year outcomes[J]. Ophthalmology, 2010, 117(12):2387-2394.
6.	Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI study:phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema[J]. Ophthalmology, 2011, 118(9):1819-1826.
7.	黎晓新.普及推广"中国老年性黄斑变性临床诊断治疗路径", 规范老年性黄斑变性的诊断治疗[J].中华眼底病杂志, 2013, 29(4):341-342.
8.	Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12-month randomized phase 2 study:AURORA study[J]. Ophthalmology, 2014, 121(9):1740-1747.
9.	中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制订委员会.中国老年性黄斑变性临床诊断治疗路径[J].中华眼底病杂志, 2013, 29(4):343-355.
10.	Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration[J]. Ophthalmology, 2012, 119(12):2537-2548.
11.	Wolf S, Balciuniene VJ, Laganovska G, et al. Radiance:a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia[J]. Ophthalmology, 2014, 121(3):682-692.
12.	Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy:6-month results[J]. Br J Ophthalmol, 2010, 94(3):297-301.
13.	Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema[J]. Arch Ophthalmol, 2009, 127(3):245-251.

1. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration[J]. Retina, 2006, 26(8):859-870.
2. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration:a report by the American Academy Of Ophthalmology[J]. Ophthalmology, 2008, 115(10):1837-1846.
3. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration:two-year results of the ANCHOR study[J]. Ophthalmology, 2009, 116(1):57-65.
4. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration:PIER study year 1[J]. Am J Ophthalmol, 2008, 145(2):239-248.
5. Campochiaro PA, Hafiz G, Channa R, et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions:two-year outcomes[J]. Ophthalmology, 2010, 117(12):2387-2394.
6. Do DV, Schmidt-Erfurth U, Gonzalez VH, et al. The DA VINCI study:phase 2 primary results of VEGF trap-eye in patients with diabetic macular edema[J]. Ophthalmology, 2011, 118(9):1819-1826.
7. 黎晓新.普及推广"中国老年性黄斑变性临床诊断治疗路径", 规范老年性黄斑变性的诊断治疗[J].中华眼底病杂志, 2013, 29(4):341-342.
8. Li X, Xu G, Wang Y, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12-month randomized phase 2 study:AURORA study[J]. Ophthalmology, 2014, 121(9):1740-1747.
9. 中华医学会眼科学分会眼底病学组中国老年性黄斑变性临床指南与临床路径制订委员会.中国老年性黄斑变性临床诊断治疗路径[J].中华眼底病杂志, 2013, 29(4):343-355.
10. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration[J]. Ophthalmology, 2012, 119(12):2537-2548.
11. Wolf S, Balciuniene VJ, Laganovska G, et al. Radiance:a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia[J]. Ophthalmology, 2014, 121(3):682-692.
12. Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy:6-month results[J]. Br J Ophthalmol, 2010, 94(3):297-301.
13. Diabetic Retinopathy Clinical Research Network (DRCR.net), Beck RW, Edwards AR, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema[J]. Arch Ophthalmol, 2009, 127(3):245-251.

Chinese Journal of Ocular Fundus Diseases

Optimization of treatment outcome and exploration of new indication in anti-vascular endothelial growth factor therapy

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content